We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Docetaxel

News List

Phase III Investigational Trial of NUBEQA® in Combination with Docetaxel and Androgen Deprivation Therapy Increases Overall Survival in Patients with mHSPC AmericanPharmaceuticalReview
December 06, 2021
The Phase III ARASENS trial investigating the use of the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) in metastatic hormone-sensitive prostate cancer (mHSPC) has met its primary endpoint. In the ARASENS trial, NUBEQA in combination...
Athenex Announces License Agreement with PharmaEssentia for Oradoxel (Oral Formulation of Docetaxel) in Several Areas in Asia pharmafocusasia
December 03, 2018
Athenex, Inc., a global biopharmaceutical company dedicated to the research of new therapies for cancer and related diseases, Development and commercialization......